compound 51 [Mallinger et al., 2016]   Click here for help

GtoPdb Ligand ID: 9170

Compound class: Synthetic organic
Comment: Compound 51 is a potent and selective CDK8/19 inhibitor [3]. It is one of the compounds claimed in patent WO2016009076 [4]. Compound 51 hasa similar inhibitory potency as CCT251545, but is built on a modified chemical scaffold [3]. This is a type I inhibitor, binding in a DMG-in mode.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 99.16
Molecular weight 414.18
XLogP 2.43
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COC1CN(C1)C(=O)c1ccc2c(n1)c(cnc2N)c1ccc(cc1)c1cnn(c1)C
Isomeric SMILES COC1CN(C1)C(=O)c1ccc2c(n1)c(cnc2N)c1ccc(cc1)c1cnn(c1)C
InChI InChI=1S/C23H22N6O2/c1-28-11-16(9-26-28)14-3-5-15(6-4-14)19-10-25-22(24)18-7-8-20(27-21(18)19)23(30)29-12-17(13-29)31-2/h3-11,17H,12-13H2,1-2H3,(H2,24,25)
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CDK8, and its closely related isoform CDK19, are oncogenic transcription-regulating kinases. CDK8 depletion does not inhibit the growth of normal cells. CDK8 is a regulator of several transcriptional programs involved in carcinogenesis (such as the Wnt/β-catenin and TGFβ signaling pathways). CDK8 is reported to be oncogenic in melanoma [2] and colon cancers [1]. CDK8 is upregulated and amplified in a subset of human colon tumours and is required for colon cancer proliferation in vitro. Inhibitors of CDK8/19 are therefore being developed for use in oncology.